Healthcare
Lyell Immunopharma, Inc.(LYEL)
Live Price
Offline$12.31
+2.84% today
1Y Change
+31.25%
Window
Jun 26, 2025 โ Jun 22, 2026
- Market Cap
- $490.00M
- Revenue Growth
- -41.0%
- EPS Growth
- -1126.0%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 26, 2025 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Lyell Immunopharma, Inc. (LYEL) is a Healthcare stock with a market cap of $490.00M and listed on NASDAQ. The stock last traded around $12.31 and up 31.3% across the available one-year price window (Jun 26, 2025 โ Jun 22, 2026). Baseline metrics include revenue growth of -41.0%, EPS growth of -1126.0%, a dividend yield of 0.0%. What stands out right now is revenue -41.0%, EPS -1126.0%, free cash flow +7.4% with operating margin -566038.9% and ROIC -70.1%. Valuation already assumes a fairly strong business story at price/sales 13498.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines LYEL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-41.0% vs +7.6% peer median
Operating Margin
Below sector median
-566038.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -41.0% and EPS is at -1126.0%, with operating margin around -566038.9%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -11.6% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | -0.1% | -16.2% | -31.3% |
2026 Mar 12, 2026 | -257.2% | -14.2% | -16.2% | -9.6% |
2025 Nov 12, 2025 | +24.2% | -1.2% | -2.3% | +89.5% |
Benchmark Edge
LYEL vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
LYEL
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
LYEL Max Drawdown
-68.99%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for LYEL and SPY.
Company Overview
Lyell Immunopharma, Inc.
NASDAQ Global Select
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
- Leadership
- Lynn Seely
- IPO Date
- Jun 17, 2021
- Employees
- 300
- Street Address
- 201 Haskins Way
- Mailing
- South San Francisco, CA, 94080
- Region
- South San Francisco, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 695 0677
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 13498.1
- Price/Book
- 1.4
Growth
- Revenue
- -41.0%
- EPS
- -1126.0%
- Free Cash Flow
- +7.4%
Profitability
- Gross Margin
- -6558.3%
- Operating Margin
- -566038.9%
- Net Margin
- -762355.6%
- ROE
- -90.5%
- ROIC
- -70.1%
Balance Sheet
- Debt/Equity
- 0.17
- Current Ratio
- 5.28
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.